Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2. Patients with recurrent UCS with HER2 immuno...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-05, Vol.41 (15), p.2789-2799
Hauptverfasser:	Nishikawa, Tadaaki, Hasegawa, Kosei, Matsumoto, Koji, Mori, Masahiko, Hirashima, Yasuyuki, Takehara, Kazuhiro, Ariyoshi, Kazuya, Kato, Tomoyasu, Yagishita, Shigehiro, Hamada, Akinobu, Kawasaki, Mamiko, Kawashima, Satoshi, Tomatsuri, Sawako, Nagasaka, Yukari, Yoshida, Hiroshi, Machida, Ryunosuke, Hirakawa, Akihiro, Nakamura, Kenichi, Yonemori, Kan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinosarcoma - genetics Carcinosarcoma - therapy Female Humans Immunoconjugates - adverse effects ORIGINAL REPORTS Receptor, ErbB-2 - metabolism Trastuzumab Uterine Neoplasms - genetics Uterine Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!